Payment overview · 2025
General Payments
$115.93
6 reported records · 3 companies
Healthcare provider profile · identity verified
Rafael Lopez, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SAN BENITO, TX · NPI 1609873058
Verified facts
What the public records show
CMS Open Payments records show Rafael Lopez, M.D. received $115.93 in general payments during 2025 across 6 reported records.
Lilly USA, LLC accounted for 50.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.36 | 50.3% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.04 | 36.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.53 | 13.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $115.93 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $58.36 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $42.04 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 149 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
149 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
192 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 963 | 334 |
| Losartan Potassium | Losartan Potassium | 625 | 193 |
| Metformin Hcl | Metformin Hcl | 561 | 178 |
| Lisinopril | Lisinopril | 510 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 438 | 135 |
| Simvastatin | Simvastatin | 396 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 360 | 105 |
| Omeprazole | Omeprazole | 306 | 123 |
| Gabapentin | Gabapentin | 251 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 242 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 238 | 94 |
| Tamsulosin Hcl | Tamsulosin Hcl | 235 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 221 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 66 |
| Jardiance | Empagliflozin | 192 | 49 |
| Alendronate Sodium | Alendronate Sodium | 187 | 78 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 172 | 46 |
| Farxiga | Dapagliflozin Propanediol | 149 | 43 |
| Sertraline Hcl | Sertraline Hcl | 144 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 143 | 57 |
| Eliquis | Apixaban | 143 | 33 |
| Ibuprofen | Ibuprofen | 140 | 74 |
| Furosemide | Furosemide | 139 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 126 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 47 |
| Glipizide | Glipizide | 119 | 39 |
| Carvedilol | Carvedilol | 117 | 34 |
| Metformin Hcl Er | Metformin Hcl | 116 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 97 | 26 |
| Ozempic | Semaglutide | 91 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 26 |
| Finasteride | Finasteride | 87 | 35 |
| Januvia | Sitagliptin Phosphate | 84 | 21 |
| Meloxicam | Meloxicam | 83 | 46 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 82 | 65 |
| Amoxicillin | Amoxicillin | 76 | 70 |
| Mupirocin | Mupirocin | 74 | 41 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 70 | 61 |
| Rybelsus | Semaglutide | 70 | 19 |
| Trazodone Hcl | Trazodone Hcl | 70 | 24 |
| Enalapril Maleate | Enalapril Maleate | 67 | 18 |
| Glipizide Er | Glipizide | 65 | 25 |
| Lorazepam | Lorazepam | 65 | 15 |
| Hydrocortisone | Hydrocortisone | 64 | 41 |
| Naproxen | Naproxen | 61 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | 17 |
| Tramadol Hcl | Tramadol Hcl | 58 | suppressed |
| Cephalexin | Cephalexin | 56 | 54 |
| Buspirone Hcl | Buspirone Hcl | 55 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 22 |
| Ezetimibe | Ezetimibe | 54 | 17 |
| Donepezil Hcl | Donepezil Hcl | 53 | 16 |
| Mirtazapine | Mirtazapine | 53 | 14 |
| Montelukast Sodium | Montelukast Sodium | 53 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 16 |
| Nystatin | Nystatin | 50 | 26 |
| Atenolol | Atenolol | 47 | 15 |
| Methylprednisolone | Methylprednisolone | 46 | 40 |
| Levofloxacin | Levofloxacin | 42 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 14 |
| Sucralfate | Sucralfate | 39 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | 12 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 38 | suppressed |
| Potassium Chloride | Potassium Chloride | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 13 |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Trulicity | Dulaglutide | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 12 |
| Baclofen | Baclofen | 34 | 23 |
| Myrbetriq | Mirabegron | 34 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 14 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 29 | 26 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Famotidine | Famotidine | 27 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Prednisone | Prednisone | 26 | 14 |
| Alprazolam | Alprazolam | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | 11 |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 19 |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 15 | 15 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Pro Comfort Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $115.93 · 6 records | Lilly USA, LLC | FARXIGA, MOUNJARO, REXULTI, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error